Company:  EXELIXIS, INC. (EXEL)
Form Type:  10-Q
Filing Date:  8/9/2022 
CIK:  0000939767 
Address:  1851 HARBOR BAY PARKWAY 
City, State, Zip:  ALAMEDA, California 94502 
Telephone:  (650) 837-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$15.68  
Change: 
-0.16 (-1.01%)  
Trade Time: 
Sep 30  
Market Cap: 
$5.05B
Trade EXEL now with

© 2022  
Description of Business
Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care. Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
          CASH FLOW
          INCOME STATEMENT
      Item 2. Management's Discussion and Analysis of Financial ...
        BENEFICIAL OWNERS
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL ...